Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD388 Phase 1 Safety and PK in Healthy Subjects
NCT05285137Phase 1Completed
- Sponsor
- Cidara Therapeutics
- Start
- Mar 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules, Fc Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of retezrelvir in influenza (7 arms), sponsored by Cidara Therapeutics. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events After a Single Dose of CD388 at Day 374 and Severity of TEAEs After a Single Dose of CD388 at Day 374. Started Mar 2022; status: completed.
02
Drugs
retezrelvir
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05285137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05285137.